Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Lixte Biotechnology Holdings Inc is a biotechnology business based in the US. Lixte Biotechnology shares (LIXT) are listed on the NASDAQ and all prices are listed in US Dollars. Lixte Biotechnology employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.75 |
|---|---|
| 52-week range | $0.66 - $4.12 |
| 50-day moving average | $1.01 |
| 200-day moving average | $1.51 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.49 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.754 from 2022-06-28
| 1 week (2022-06-22) | -2.08% |
|---|---|
| 1 month (2022-05-27) | -0.79% |
| 3 months (2022-03-30) | -38.70% |
| 6 months (2021-12-30) | -34.43% |
| 1 year (2021-06-30) | -75.12% |
|---|---|
| 2 years (2020-06-26) | N/A |
| 3 years (2019-06-28) | 1 |
| 5 years (2017-06-29) | 523.14% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -69.22% |
| Return on equity TTM | -119.74% |
| Profit margin | 0% |
| Book value | $0.09 |
| Market capitalisation | $13.4 million |
TTM: trailing 12 months
We're not expecting Lixte Biotechnology to pay a dividend over the next 12 months.
You may also wish to consider:
Lixte Biotechnology's shares were split on a 1:6 basis on 19 November 2020. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Lixte Biotechnology shares which in turn could have impacted Lixte Biotechnology's share price.
Over the last 12 months, Lixte Biotechnology's shares have ranged in value from as little as $0.66 up to $4.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lixte Biotechnology's is -1.1724. This would suggest that Lixte Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lixte Biotechnology has bucked the trend.
To put Lixte Biotechnology's beta into context you can compare it against those of similar companies.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. ; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.